OS09.8 RANDOMIZED PLACEBO-CONTROLLED TRIAL OF AUTOLOGOUS FORMALIN-FIXED TUMOR VACCINE FOR NEWLY DIAGNOSED GLIOBLASTOMA

Y. Muragaki¹, T. Maruyama¹, E. Ishikawa², M. Nitta¹, S. Ikuta¹, T. Yamamoto², K. Tsuboi², A. Matsumura², H. Nakamura³, J. Kuroda³, T. Abe⁴, T. Abe⁴; ¹Tokyo Women's Medical University, Tokyo, Japan, ²University of Tsukuba, Tsukuba, Japan, ³Kumamoto University, Kumamoto, Japan, ⁴Saga University, Saga, Japan.

INTRODUCTION: There is a growing interest in development of novel therapeutic modalities based on tumor-specific immune reactions for management of glioblastoma multiforme (GBM). Autologous formalin-fixed tumor vaccine (AFTV) was designed by our group for *in vivo* induction of killer lymphocytes and activation of T-lymphocyte (Nat Med 1995, 1996). In first trial for recurrent GBM, 3 responding patients survived more than 20 months after AFTV administration (Cancer Sci, 2007). Efficacy of AFTV concomitant with fractionated radiotherapy (FRT) without chemotherapy with temozolomide (TMZ) in patients with newly-diagnosed GBM was evaluated in prospective phase I/IIa trial (C00002), which showed median overall survival (OS) of 19.8 months (J Neurosurg, 2011). Another prospective multicenter phase I/IIa trial (UMIN01426) for evaluation of the combined use of AFTV and standard chemoradiotherapy with TMZ (AFTV+RT/TMZ; Stupp regimen) for newly-diagnosed GBM, showing median progression-free survival (PFS) and OS of 8.2 and 22.2 months, respectively (J Neurosurg, 2013). Currently, prospective multicenter placebo-controlled double-blind phase IIb/III trial (UMIN10602) directing on evaluation of AFTV+RT/TMZ for newly-diagnosed GBM is ongoing and recruiting of patients for its phase IIb part has been finished in January 2016. We here report preliminary results before a key opening. **METHODS:** The phase IIb/III study investigated the AFTV plus chemoradiotherapy with temozolomide (AFTV + RT/TMZ; Stupp protocol) versus placebo plus chemoradiotherapy (Pla + RT/TMZ) for newly diagnosed glioblastoma. After resection surgery, patients with glioblastoma were randomly assigned 1:1 to receive AFTV (2 courses; 3 times, once a week) + RT/TMZ or Pla + RT/TMZ until disease progression. The primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), objective response rate, QOL, and safety. **RESULTS:** Adult 63 patients with supratentorial glioblastoma were enrolled, although 3 patients withdraw the consents. Among 60 patients for full analysis set, baseline characteristics were balanced. The median age was 61 years old, men vs. women were 33 vs. 27, and the median resection rate was 95%. Mean follow-up period was 15.8 months. The median PFS was 14.2 months and 6-month PFS was 75% both for AFTV+RT/TMZ and Pla+RT/TMZ. The median PFS was 21.4 months and 1-year survival was 86% both for AFTV+RT/TMZ and Pla+RT/TMZ. No severe adverse events caused by AFTV or placebo were observed. **CONCLUSION:** The phase IIb part of the trial has been done safely and trial would be promising because the median PFS for both groups was more than a year. If AFTV+RT/TMZ would show longer survival time compared to Pla+RT/TMZ by the key open, a phase III would be warranted.

OS09.9 IDENTIFICATION OF IDH1R132H-SPECIFIC T CELL RECEPTORS FROM GLIOMA PATIENTS AND FROM MHC-HUMANIZED MICE

L. Bunse^{1,2,3}, T. Bunse^{1,3}, K. Sanghvi¹, E. Green¹, F. Sahn⁴, T. Omokoko⁵, U. Sahin⁵, M. Schmitt⁶, W. Wick^{7,8}, M. Platten^{1,3}; ¹DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany, ²Department of Neurology, Heidelberg University Medical Center; National Center for Tumor Diseases Heidelberg, German Cancer Consortium (DKTK), Heidelberg, Germany, ³Department of Neurology, University Hospital Mannheim, Mannheim, Germany, ⁴Department of Neuropathology, University Hospital Heidelberg; Clinical Cooperation Unit Neuropathology, DKFZ, Heidelberg, Germany, ⁵BioNTech Cell & Gene Therapies GmbH, Mainz, Germany, ⁶Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany, ⁷DKTK Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

INTRODUCTION: Central to an effective immunotherapy for gliomas are the discovery of tumor-specific antigens and the development of therapeutic strategies that effectively exploit them. One such example is the mutation in the gene encoding for isocitrate dehydrogenase 1 (IDH1). IDH1R132H is present in 80 % of grade II and grade III gliomas and secondary glioblastomas. We have previously shown that an IDH1R132H-peptide vaccine evokes an MHC class II-restricted T-helper cell response and is therapeutic in an MHC-humanized mouse sarcoma model. **MATERIALS AND METHODS:** To identify IDH1R132H-specific T-cell receptors (TCRs), a T-cell line was generated from splenocytes of vaccinated MHC-humanized mice by re-stimulations with autologous IDH1R132Hp¹³²⁻¹⁴²-loaded splenocytes. Subsequently, T-cells were sorted for IDH1R132H-specificity exploiting IDH1R132H-specific HLA-DR1-tetramers. In addition, we analyzed IDH1R132H-reactive T-cells from an HLA-DR13+ and HLA-DR16+ patient with progressive IDH1R132H+ astrocytoma and IDH1R132H-spe-

cific immune response. **RESULTS:** Sequencing analyses of the V-J or V-D-J regions of the *TRA* and *TRB* genes, respectively, revealed three dominant *TRA* and *TRB* sequences in the established murine T-cell line. Full length murine TCRs were constructed by pairing the two most dominant *TRA* and *TRB* sequences and cloned into expression vectors for functional validation. T-cells from the glioma patient were expanded *in vitro* and subjected to single-cell-sorting and subsequent TCR sequencing. 11 different TCR sequences have been identified. **CONCLUSIONS:** Identification of IDH1R132H-specific TCRs may expand the immunotherapeutic spectrum, e.g. enable adoptive T-cell transfer, for IDH1R132H-mutated gliomas.

OS10 ABSTRACT HIGHLIGHTS

OS10.1 GENOMIC LANDSCAPE OF PITUITARY ADENOMAS

W. L. Bi¹, N. F. Greenwald¹, M. Abedalthagafi², P. Horowitz³, E. R. Laws¹, R. Beroukhi⁴, I. F. Dunn¹; ¹Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States, ²Saudi Human Genome Project Lab, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia, ³Department of Surgery, The University of Chicago, Chicago, IL, United States, ⁴Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States.

INTRODUCTION: The clinical outcome of pituitary adenomas can be difficult to predict consistently. **METHODS:** We characterized the genomic profile of 150 pituitary adenomas using next-generation sequencing and assessed the correlation between molecular and pathologic characteristics. These adenomas included hormonally active and inactive tumors, ones with typical or atypical histology, and ones that were primary or recurrent. **RESULTS:** We observed two classes of pituitary adenomas based on their molecular profile. One class, encompassing one-third of the samples, had widespread genomic disruption with high rates of chromosome arm-level copy-number alterations. The other class tumors exhibited somatic copy-number alterations involving less than 6% of the genome. Levels of genomic disruption correlated with tumor pathology, as 75% of the disrupted subclass were functional adenomas or atypical null-cell adenomas, compared to only 13% of the less disrupted groups. Despite these high rates of genomic disruption, we detected relatively few focal events, which is unusual among highly disrupted cancers. We validated our finding by looking at previously published gene-expression data, and found that the disrupted subtype harbored more variable gene-expression profiles than quiet tumors. We validated these observations from the discovery cohort in an independent cohort of over 100 pituitary adenomas using a targeted clinical sequencing panel, and confirmed that a CLIA-approved assay was able to discriminate between disrupted and non-disrupted tumors. Furthermore, we recapitulated the known patterns of GNAS driver alterations in growth hormone secreting adenomas. **CONCLUSION:** Sporadic pituitary adenomas have distinct copy number profiles that associate with hormonal and histologic subtypes and influence gene expression. These results contribute to the growing repertoire of molecular data that have been generated in pituitary tumors, and will guide future efforts of pituitary tumor classification and risk-stratification.

OS10.2 R-2-HYDROXYGLUTARATE SHAPES THE IMMUNE MICROENVIRONMENT IN IDH1-MUTANT GLIOMAS

M. Friedrich^{1,2}, L. Bunse^{1,2}, T. Bunse^{1,2}, S. Pusch³, F. Sahn^{3,4}, K. Sanghvi¹, M. Steadman⁵, B. Niemeier⁶, W. Wick^{7,8}, M. Platten^{1,2,8}; ¹Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany, ²Department of Neurology, Heidelberg University Medical Center; National Center for Tumor Diseases (NCT), Heidelberg, Germany, ³Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany, ⁴Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany, ⁵Agios Pharmaceuticals, Inc., Cambridge, MA, United States, ⁶Molecular Biophysics, Center for Integrative Physiology and Molecular Medicine, School of Medicine, Saarland University, Homburg, Germany, ⁷Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany, ⁸Department of Neurology, University Hospital Mannheim, Mannheim, Germany.

BACKGROUND: IDH1-mutant tumors form the majority of grade II and grade III gliomas, qualifying as a new entity in the 2016 WHO classification of CNS tumors. We have previously shown that a peptide vaccine encoding the IDH1(R132H) epitope evokes an MHC II-restricted CD4+ T Helper-1 cell (Th1) immune response and is therapeutic in an MHC-humanized A2.DR1 mouse tumor model. Ongoing efforts focus on further unleashing both the innate and adaptive immune system in targeting IDH1(R132H)-mutant gliomas. While the tumor-cell-intrinsic consequences of R-2-hydroxyglutarate (R-2-HG)-production, rendered by the IDH1-mutation, are well

characterized, potential paracrine effects influencing antitumor immunity remain enigmatic. However, they are important to decipher, as immunotherapies targeting IDH1-mutant gliomas are emerging. **AIM:** This study aimed at characterizing a potential cell-specific modulatory role of the oncometabolite R-2-HG in shaping the immune microenvironment of IDH1-mutant gliomas. **METHODS AND RESULTS:** By means of expression dataset analyses, syngeneic murine tumor models and human glioma tissue, as well as a novel astrocyte-specific IDH1R132H-knock-in model, we demonstrate that R-2-HG impairs endogenous and IDH1(R132H)-specific antitumor T cell immunity. This is underlined by functional and transcriptomic analyses of myeloid cells indicating a R-2-HG-driven induction of tolerogenicity and compromised antigen presentation. Metabolomic profiling was complemented by mitochondrial respiration assays, calcium measurements and pathway analyses in primary human and mouse immune cells to delineate key molecular mechanisms by which tumor-derived R-2-HG corrupts the glioma immunoenvironment. The functional relevance of R-2-HG-mediated impairment of antitumor immunity was demonstrated in vivo and potential pharmacological strategies abrogating its effects were assessed. **CONCLUSION:** Glioma-derived R-2-HG impairs antitumor immunity by affecting both infiltrating T-cells and the associated myeloid compartment, thus contributing to tumorigenesis and resistance to therapy. Immunotherapeutic strategies against IDH-mutant gliomas may benefit from approaches to prevent excess R-2-HG production or its uptake by immune cells.

OS10.3 RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143

D. A. Reardon^{1a}, A. Omuro^{2a}, A. A. Brandes³, J. Rieger^{4,5}, A. Wick⁶, J. Sepulveda⁷, S. Phuphanich⁸, P. de Souza⁹, M. S. Ahluwalia¹⁰, M. Lim¹¹, G. Vlahovic^{12b}, J. Sampson^{12b}; ¹Dana-Farber Cancer Institute and Harvard University School of Medicine, Boston, MA, United States, ²Memorial Sloan-Kettering Cancer Center, New York, NY, United States, ³AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy, ⁴Klinikum der Goethe-Universität, Frankfurt, Germany, ⁵University of Tübingen, Tübingen, Germany, ⁶Neurology Clinic, University of Heidelberg, National Center for Tumor Diseases, Heidelberg, Germany, ⁷Hospital Universitario 12 De Octubre, Madrid, Spain, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, United States, ⁹University of Western Sydney School of Medicine, Liverpool, Australia, ¹⁰Cleveland Clinic, Cleveland, OH, United States, ¹¹The Johns Hopkins Hospital, Baltimore, MD, United States, ¹²Duke University Medical Center, Durham, NC, United States.

BACKGROUND: Despite available treatment options for patients (pts) with recurrent glioblastoma (GBM), < 5% of pts survive 5 years beyond initial diagnosis, and no single-agent therapy has demonstrated a survival benefit in the second-line setting, including bevacizumab (bev), which is approved for the treatment of recurrent disease. Nivolumab (nivo), a fully human IgG4 monoclonal antibody that inhibits the programmed death 1 receptor, has provided clinical benefit in multiple cancer types. In cohort 2 of the open-label, phase 3 CheckMate 143 study (NCT02017717), the efficacy and safety of nivo was compared with that of bev in pts with GBM experiencing their first recurrence after prior radiotherapy (RT) and temozolomide (TMZ). **METHODS:** Pts with no prior VEGF therapy were randomized 1:1 to receive nivo 3 mg/kg Q2W or bev 10 mg/kg Q2W until confirmed disease progression; pts were stratified by the presence/absence of measurable disease. The primary endpoint was overall survival (OS); secondary endpoints were 12-mo OS rate and investigator-assessed progression-free survival (PFS) and objective response rate (ORR) per Response Assessment in Neuro-Oncology criteria. **RESULTS:** At the time of final analyses (Jan 20, 2017), 369 pts were randomized to the nivo (n = 184) or bev (n = 185) treatment arms; of these pts, 182 received nivo and 165 received bev. At baseline, most pts in the nivo (83%) and bev (84%) arms had measurable disease, and 40% (nivo) and 43% (bev) of pts required corticosteroids, with 14% (nivo) and 15% (bev) receiving ≥ 4 mg/day. Deaths were reported in 154 (nivo) and 147 (bev) pts; median OS was 9.8 mo with nivo and 10.0 mo with bev, and the 12-mo OS rate was 42% in both arms. PFS medians were 1.5 mo (nivo) and 3.5 mo (bev). Among evaluable pts treated with nivo (n = 153) or bev (n = 156), ORRs were 8% (nivo) and 23% (bev); duration of response medians were 11.1 mo (nivo) and 5.3 mo (bev). Treatment-related AEs (TRAEs) occurred in 57% (nivo) and 58% (bev) of pts; the most common TRAEs ($\geq 10\%$ of pts in either arm; nivo vs bev) were fatigue (21% vs 14%) and hypertension (1% vs 22%). Grade 3–4 TRAEs were reported in 18% (nivo) and 15% (bev) of pts. Serious AEs (all causality) were reported in 46% (nivo) and 35% (bev) of pts; seizure (8% vs 6%) and malignant neoplasm progression (11% vs 7%) were the only serious AEs reported in $\geq 5\%$ of pts in either arm. AEs leading to discontinuation occurred in 10% (nivo) and 15% (bev) of pts. **CONCLUSIONS:** Nivo did not demonstrate an improved OS compared with bev in pts with recurrent GBM. The ORR was lower with nivo than bev; however, responses with nivo were more durable. The safety profile of nivo was consistent with that observed in other tumor types. Studies of nivo in combination with RT $\pm$ TMZ in pts with newly diagnosed GBM are ongoing.

OS11 GLIOMAS

OS11.1 TEMOZOLOMIDE (TMZ) 1 WEEK ON/1 WEEK OFF AS INITIAL TREATMENT FOR HIGH RISK LOW GRADE OLIGODENDROGLIAL TUMORS: A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY

A. Pellerino, F. Franchino, A. Pace, C. Carapella, C. Dealis, M. Caroli, M. Faedi, C. Bompreszi, R. Rudà, R. Soffietti; Department of Neuro-Oncology, University and City of Health and Science Hospital on behalf the AINO, Turin, Italy.

INTRODUCTION: The efficacy of dose-dense temozolomide (TMZ, 1 week on/1 week off) in grade II gliomas is not well known, and the impact could depend on the molecular subtype. In this regard prospective data are still missing. **PATIENTS AND METHODS:** Between 2006 and 2010 a single arm phase II study on 60 evaluable patients with grade II oligodendroglial tumors (WHO 2007) was performed. Inclusion criteria were as follows: 1) age ≥ 18 years; 2) KPS ≥ 70 ; 3) biopsy-proven grade II oligodendroglioma or oligoastrocytoma according to WHO 2007; 4) presence of a measurable residual tumor after surgery. The primary endpoint of the study was tumor response on MRI according to RANO criteria, while the secondary endpoints were progression-free survival (PFS), overall survival (OS), and seizure control according to Engel classification. Most patients (65%) had an active epilepsy at the time of start of chemotherapy. Molecular factors were available in 49/60 patients (81.7%): 21/60 (35%) patients were IDH1-2 mutated/1p19q codeleted, 4/60 (6.7%) were IDH1-2 mutated/1p19q non-codeleted and 24/60 (40%) were IDH1-2 wild-type. The median number of cycles of dose-dense TMZ was 11 (range 2–18). Median follow up was 64 months (range 7–112). **RESULTS:** Overall, response rate following dose-dense TMZ was as follows: PR in 21/60 (35%) patients, minor PR (mPR) in 14/60 (23%), SD in 21/60 (35%) and PD in 4/60 (7%). Most patients achieved the best tumor response within 6 months after the start of TMZ. Among patients with mPR and PR, 15/49 (30.6%) were IDH1-2 mutated/1p19q codeleted and 11/49 (22.4%) were IDH1-2 wild-type. PFS was 71.4% at 36 months and 28.6% at 60 months with a median value of 46 months in the IDH1-2 mutated/1p19q codeleted subgroup, while PFS was 45.8% at 36 months and 25% at 60 months with a median value of 34 months in the IDH1-2 wild-type subgroup. OS was 90.5% at 36 months and 66.7% at 60 months with a median value of 76 months in the IDH1-2 mutated/1p19q codeleted subgroup, while OS was 66.7% at 36 months and 50% at 60 months with a median value of 60 months in the IDH1-2 wild-type subgroup. The number of patients with IDH1-2 mutated but not 1p19q codeleted tumors was too small to allow meaningful correlations with response and survival. Seizure improvement was achieved in 29/34 patients (85%) following TMZ: 17/33 (52%) patients at 12 months and 18/29 (62.1%) at 24 months were seizure-free (Engel class I). The time of maximal seizure response was earlier than that observed on MRI (3 months vs 6 months). **CONCLUSIONS:** Dose-dense TMZ has shown a significant activity in terms of tumor and seizure control, especially in IDH1-2 mutated/1p19q codeleted patients. Seizure reduction could represent an early indicator of response to chemotherapy and maybe predict the duration of response.

OS11.2 RISK-ADJUSTED SURVIVAL OUTCOMES FOR AND FEATURES OF 1P/19Q CODELETION OLIGODENDROGLIOMAS

B. Iorgulescu, C. Zogg, W. Gornley, E. Chiocca, D. Reardon, P. Wen, D. Haas-Kogan, B. Alexander, K. Ligon, T. Smith; Brigham and Women's Hospital, Boston, MA, United States.

BACKGROUND: Oligodendrogliomas (OGs) are diffuse gliomas defined by IDH mutation and 1p/19q codeletion, in which response to treatment and survival are dictated not by histology, but by molecular subtypes. **METHODS:** The US NCDB was queried for OG patients newly-diagnosed from 2004–2014. Patient and tumor factors were compared by Chi2 or t test. Overall survival (OS) was assessed by Cox proportional hazards and Kaplan-Meier methods, stratified by histology, grade, and codeletion status, and risk adjusted for age, sex, race, Charlson's comorbidity index, insurance, facility location, chemoradiotherapy, and tumor location, laterality, and size. **RESULTS:** 14,948 patients with gliomas with OG histology remained after exclusion, 67% (n=10,075) were WHO gr2, 33% were WHO gr3 (i.e. anaplastic), and 36% displayed mixed oligoastrocytoma histology. Complete 1p/19q data were available in 20% (n=2,920). Compared to gr2 non-codeleted cases, codeleted OGs presented at an older median age of 43 yrs (IQR: 25–52; vs. 38 yrs, IQR: 25–51, p<0.0001). Notably, 67% were MGMT methylated (vs. 38%, p<0.001) and 75% arose in the frontal lobe (vs. 56%, p<0.001), and 12% in the temporal lobe (vs. 30%). For treatment, 41% of gr2 codeleted OGs received chemotherapy (vs. 36%, p<0.01), 28% received radiotherapy (vs. 41%, p<0.001), 86% underwent surgery, 55% of which were GTR. In risk-adjusted analysis of gr2 OGs, codeletion was associated with significantly improved OS (HR 0.44, 95%CI: 0.27–0.72, p=0.001), with 2-yr and 5-yr OS rates of 96% (95%CI: 94–97) and 87% (95%CI: 84–90), respectively; vs. 87% (95%CI: 84–90) and 70% (95%CI: